128940.KS
Hanmi Pharmaceutical Co., Ltd. [128940.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
128940.KS Stock Summary
Top 128940.KS Correlated Resources
128940.KS
Top 10 Correlated ETFs
128940.KS
Top 10 Correlated Stocks
128940.KS
In the News
128940.KS Financial details
Company Rating
Strong Buy
Market Cap
3262.84B
Income
80.78B
Revenue
1330.85B
Book val./share
72995.89
Cash/share
-
Dividend
-
Dividend %
-
Employees
2.12K
Optionable
No
Shortable
Yes
Earnings
26 Jan 2023
P/E
39.16
Forward P/E
-
PEG
0.68
P/S
2.38
P/B
3.62
P/C
-
P/FCF
14.92
Quick Ratio
-
Current Ratio
1.08
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
6.74K
EPS next Y
-
EPS next Q
-
EPS this Y
460.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.58%
Revenue last 5Y
5.59%
Revenue Q/Q
7.9%
EPS Q/Q
37.74%
-
-
-
-
SMA20
-9.21%
SMA50
-1.4%
SMA100
-12.35%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
10%
ROC
0.12%
Gross Margin
53%
Oper. Margin
12%
Profit Margin
6%
Payout
-
Shs Outstand
12.45M
Shs Float
6.28M
-
-
-
-
Target Price
-
52W Range
219117.64-323039.22
52W High
-18.28%
52W Low
+20.48%
RSI
47.03
Rel Volume
1.1
Avg Volume
31.24K
Volume
34.45K
Perf Week
1.93%
Perf Month
-8.97%
Perf Quarter
-18.52%
Perf Half Y
-13.3%
-
-
-
-
Beta
0.752151
-
-
Volatility
4348.35%, 16592.5%
Prev Close
-2.94%
Price
264000
Change
-0.75%
128940.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 78.35K | 86.34K | 94.59K | 89.66K | 100.27K | |
| Net income per share | 5.17K | 2.12K | 4.43K | 996.7 | 5.59K | |
| Operating cash flow per share | -5.38K | 2.21K | 1.06K | 12.63K | 16.83K | |
| Free cash flow per share | -27.8K | -15.74K | -14.09K | 7.81K | 13.96K | |
| Cash per share | 12K | 8.39K | 9.18K | 12.34K | 17.65K | |
| Book value per share | 60.84K | 59.76K | 61.48K | 60.84K | 66.92K | |
| Tangible book value per share | 63.83K | 61.92K | 64.21K | 63.26K | 70.68K | |
| Share holders equity per share | 60.84K | 59.76K | 61.48K | 60.84K | 66.92K | |
| Interest debt per share | 41.62K | 55.29K | 74.45K | 68.93K | 64.41K | |
| Market cap | 6560.4B | 4773.54B | 3259.15B | 4505.47B | 2963.73B | |
| Enterprise value | 6989.38B | 5337.39B | 4004.6B | 5161.5B | 3510.77B | |
| P/E ratio | 108.55 | 191.78 | 62.54 | 376.73 | 44.22 | |
| Price to sales ratio | 7.16 | 4.7 | 2.93 | 4.19 | 2.46 | |
| POCF ratio | -104.29 | 183.72 | 261.85 | 29.73 | 14.68 | |
| PFCF ratio | -20.17 | -25.77 | -19.64 | 48.09 | 17.69 | |
| P/B Ratio | 9.22 | 6.79 | 4.5 | 6.17 | 3.69 | |
| PTB ratio | 9.22 | 6.79 | 4.5 | 6.17 | 3.69 | |
| EV to sales | 7.63 | 5.25 | 3.6 | 4.8 | 2.92 | |
| Enterprise value over EBITDA | 71.71 | 49.56 | 26.36 | 50.11 | 18.01 | |
| EV to operating cash flow | -111.11 | 205.42 | 321.74 | 34.06 | 17.39 | |
| EV to free cash flow | -21.49 | -28.81 | -24.13 | 55.09 | 20.96 | |
| Earnings yield | 0.01 | 0.01 | 0.02 | 0 | 0.02 | |
| Free cash flow yield | -0.05 | -0.04 | -0.05 | 0.02 | 0.06 | |
| Debt to equity | 0.28 | 0.59 | 0.76 | 0.55 | 0.38 | |
| Debt to assets | 0.52 | 0.53 | 0.57 | 0.56 | 0.52 | |
| Net debt to EBITDA | 4.4 | 5.24 | 4.91 | 6.37 | 2.81 | |
| Current ratio | 1.03 | 1.3 | 1.4 | 1.15 | 1.08 | |
| Interest coverage | 7.68 | 4.3 | 4.16 | 1.97 | 7.57 | |
| Income quality | -1.04 | 1.04 | 0.24 | 12.67 | 3.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.36 | 0.11 | 0.68 | 0.09 | |
| Sales general and administrative to revenue | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | |
| Research and developement to revenue | 0.17 | 0.16 | 0.17 | 0.2 | 0.12 | |
| Intangibles to total assets | 0.03 | 0.04 | 0.03 | 0.04 | 0.04 | |
| Capex to operating cash flow | 4.17 | -8.13 | -14.33 | -0.38 | -0.17 | |
| Capex to revenue | -0.29 | -0.21 | -0.16 | -0.05 | -0.03 | |
| Capex to depreciation | -7.19 | -4.48 | -3.22 | -0.94 | -0.39 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 84.09K | 53.33K | 78.24K | 36.94K | 91.71K | |
| ROIC | 0.08 | 0.07 | 0.07 | 0.04 | 0.1 | |
| Return on tangible assets | 0.04 | 0.02 | 0.03 | 0.01 | 0.04 | |
| Graham Net | -52.32K | -57.74K | -69.65K | -62.33K | -55.98K | |
| Working capital | 18.92B | 129.12B | 190.4B | 80.92B | 55.02B | |
| Tangible asset value | 746.72B | 728.57B | 756.02B | 759B | 848.09B | |
| Net current asset value | -210.42B | -337.86B | -429.24B | -435.76B | -304.51B | |
| Invested capital | 0.67 | 0.9 | 1.18 | 1.1 | 0.94 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 39.39B | 38.34B | 34.86B | 32.21B | 37.52B | |
| Average inventory | 270.33B | 278.15B | 317.63B | 308.54B | 279.36B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 42.69 | 34.17 | 28.45 | 23.76 | 27.41 | |
| Days of inventory on hand | 212.78 | 190.36 | 247.85 | 227.54 | 160.09 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 8.55 | 10.68 | 12.83 | 15.36 | 13.32 | |
| Inventory turnover | 1.72 | 1.92 | 1.47 | 1.6 | 2.28 | |
| ROE | 0.08 | 0.04 | 0.07 | 0.02 | 0.08 | |
| Capex per share | -22.42K | -17.95K | -15.15K | -4.82K | -2.87K |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 25.29K | 29.25K | 26.8K | 26.46K | 28.55K | |
| Net income per share | 1.95K | 1.46K | 1.63K | 1.54K | 2.12K | |
| Operating cash flow per share | 5.54K | 4.76K | 8.12K | 3.94K | 4.77K | |
| Free cash flow per share | 4.76K | 4.1K | 6.85K | 2.87K | 3.87K | |
| Cash per share | 17.39K | 17.67K | 0 | 0 | 0 | |
| Book value per share | 65.71K | 67.01K | 68.23K | 69.97K | 73K | |
| Tangible book value per share | 69.23K | 70.78K | 78.98K | 81.2K | 85.05K | |
| Share holders equity per share | 65.71K | 67.01K | 68.23K | 69.97K | 73K | |
| Interest debt per share | 62.68K | 63.13K | -283.37 | -300.47 | -307.86 | |
| Market cap | 3230.54B | 3307.13B | 3283.16B | 3690.56B | 2743.96B | |
| Enterprise value | 3770.69B | 3854.17B | 3283.16B | 3690.56B | 2743.96B | |
| P/E ratio | 34.51 | 47.33 | 42.06 | 50.08 | 27.03 | |
| Price to sales ratio | 10.66 | 9.44 | 10.22 | 11.64 | 8.02 | |
| POCF ratio | 48.63 | 57.93 | 33.76 | 78.17 | 48.05 | |
| PFCF ratio | 56.7 | 67.34 | 39.98 | 107.28 | 59.24 | |
| P/B Ratio | 4.1 | 4.12 | 4.02 | 4.4 | 3.14 | |
| PTB ratio | 4.1 | 4.12 | 4.02 | 4.4 | 3.14 | |
| EV to sales | 12.44 | 11 | 10.22 | 11.64 | 8.02 | |
| Enterprise value over EBITDA | 69.02 | 71.11 | 65.26 | 202.81 | 96.96 | |
| EV to operating cash flow | 56.76 | 67.51 | 33.76 | 78.17 | 48.05 | |
| EV to free cash flow | 66.18 | 78.48 | 39.98 | 107.28 | 59.24 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0.02 | 0.01 | 0.03 | 0.01 | 0.02 | |
| Debt to equity | 0.38 | 0.38 | 0 | 0 | 0 | |
| Debt to assets | 0.53 | 0.52 | 0.52 | 0.5 | 0.49 | |
| Net debt to EBITDA | 9.89 | 10.09 | 0 | 0 | 0 | |
| Current ratio | 1.07 | 1.08 | 1.07 | 1.06 | 1.08 | |
| Interest coverage | 7.14 | 215.16 | -12.03 | -8.77 | -12.69 | |
| Income quality | 2.84 | 3.27 | 4.98 | 2.56 | 2.25 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0.2 | 0.32 | 0.45 | |
| Sales general and administrative to revenue | 0.05 | 0.06 | 0.41 | 0.42 | 0.41 | |
| Research and developement to revenue | 0.12 | 0.12 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.04 | 0.04 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.14 | -0.14 | -0.16 | -0.27 | -0.19 | |
| Capex to revenue | -0.03 | -0.02 | -0.05 | -0.04 | -0.03 | |
| Capex to depreciation | -0.43 | -0.33 | -0.66 | -0.56 | -0.42 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 53.73K | 46.88K | 50K | 49.2K | 58.97K | |
| ROIC | 0.03 | 0.03 | 0.03 | 0.02 | 0.04 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham Net | -57.67K | -56.05K | -85.88K | -80.73K | -80.53K | |
| Working capital | 47.12B | 55.02B | 47.23B | 42.11B | 57.99B | |
| Tangible asset value | 829.6B | 848.09B | 0 | 0 | 0 | |
| Net current asset value | -335.75B | -304.51B | -302.45B | -265.3B | -220.27B | |
| Invested capital | 0.95 | 0.94 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 21.8 | 23.26 | 0 | 0 | 0 | |
| Days of inventory on hand | 179.03 | 135.85 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.13 | 3.87 | 0 | 0 | 0 | |
| Inventory turnover | 0.5 | 0.66 | 0 | 0 | 0 | |
| ROE | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Capex per share | -788.68 | -665.48 | -1.26K | -1.07K | -900.33 |
128940.KS Frequently Asked Questions
What is Hanmi Pharmaceutical Co., Ltd. stock symbol ?
Hanmi Pharmaceutical Co., Ltd. is a KR stock and trading under the symbol 128940.KS
What is Hanmi Pharmaceutical Co., Ltd. stock quote today ?
Hanmi Pharmaceutical Co., Ltd. stock price is $264000 today.
Is Hanmi Pharmaceutical Co., Ltd. stock public?
Yes, Hanmi Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 31.24K
- Market Capitalization 3262.84B
- Employee 2.12K
- CEO Mr. Jong-Soo Woo Ph.D.
- Headquarters Seoul,KR
- IPO Date 2010-07-30
-
Website
https://www.hanmipharm.com 
Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
